Trump Nominates Anti-Vaccine Expert Kennedy to Lead HHS
On November 14, 2024, President Donald Trump officially announced his intention to nominate Robert F. Kennedy Jr. to serve as Secretary of the Department of Health and Human Services (HHS) in his new administration. This decision has aroused widespread public concern and controversy.
Since 2005, Kennedy has continued to argue for a link between vaccines and autism, although this view has been widely rejected by the scientific community. He has also argued that the COVID-19 virus is "racially directed," primarily affecting whites and blacks, while Ashkenazi Jews and Chinese are less affected.
In announcing his nomination, Trump emphasized Kennedy's commitment to reforming the U.S. health care system to ensure the public is protected from harmful chemicals, pollutants, pesticides, drugs and food additives. He also said Kennedy would work to restore HHS's tradition of scientific research and increase transparency to address the nation's chronic disease epidemic.
If Trump's nomination is confirmed by the Senate, Kennedy would be responsible for leading HHS, which has a budget of $1.7 trillion, and overseeing key agencies including the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Centers for Medicare and Medicaid Services (CMS). Kennedy had previously revealed plans to lay off 600 NIH employees on his first day in office, signaling a potential major change for the agency.
The nomination has been widely discussed in medical and political circles. Many public health experts have expressed concern about Kennedy's anti-vaccine stance, arguing that it could have implications for current vaccination policies and public health strategies in the United States. At the same time, some members of the Republican Party are also wary of the nomination, fearing that it may cause unnecessary controversy.
The Senate has yet to vote on the nomination, and it remains to be seen whether Kennedy will succeed.
2026-08-20
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China’s Acrylic Emulsion Leaders Raise Prices by Up to 15% as Monomer Costs Surge
-
Japan Begins Construction of the World’s Largest Commercial Liquid Hydrogen Receiving Terminal
-
India Swings the Tariff Axe at Made-in-China: Epoxy Resins Are Just the Beginning—The Road for Chinese Chemicals Abroad Is No Longer Smooth
-
Japanese Plastics Market Accelerates its Shifts to Recycled Materials and Bioplastics
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Glyphosate Faces New UK Pressure as EU Trade Alignment Returns to the Debate
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
FDA Dye Phase-Out Push Opens a Bigger Window for Natural Color Solutions
-
From Painting Walls to Total Collapse: The RMB 152 Million Debt That Tore Off the Last Veil of Asia Chuangneng’s Paint Empire
-
Selling the Family Silver for a New Suit? Why Bohai Chemical’s Transformation Drama Got Canceled After Just Two Acts
Recommend Reading
-
Echoes of Overcapacity: The Structural Anxiety of China’s EVA Industry Chain
-
The Cold Cycle: PVC Market’s Chill and Faint Light Ahead
-
Air Liquide to Acquire Korea’s DIG Airgas for €2.85 Billion
-
UAE Withdraws from OPEC
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Supply and Demand in Delicate Balance, Acrylonitrile Market Remains Stagnant in August in China
-
Natural Rubber Market Prices Consolidate at High Levels
-
Supply Eases, Acrylonitrile Market Continues to Decline in China
-
Ample Supply, PP Prices in China Steady with a Slight Decline in August
-
Lido Limited: Polyethylene Operates Weakly